TY  - GEN
AU  - Willemze,R
AU  - Suciu,S
AU  - Muus,P
AU  - Halkes,C J M
AU  - Meloni,G
AU  - Meert,L
AU  - Karrasch,M
AU  - Rapion,J
AU  - Vignetti,M
AU  - Amadori,S
AU  - de Witte,T
AU  - Marie,J P
TI  - Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
SN  - 1432-0584
PY  - 2014///0623
KW  - Adenine Nucleotides
KW  - administration & dosage
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Arabinonucleosides
KW  - Clofarabine
KW  - Consolidation Chemotherapy
KW  - Cytarabine
KW  - Fatigue
KW  - chemically induced
KW  - Female
KW  - Gastrointestinal Diseases
KW  - Humans
KW  - Hydroxyurea
KW  - therapeutic use
KW  - Hyperbilirubinemia
KW  - Idarubicin
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - Remission Induction
KW  - Risk
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s00277-014-2056-6
ER  -